Clinical Trials Logo

Refractory B-Lineage Leukemia clinical trials

View clinical trials related to Refractory B-Lineage Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT02370160 Completed - Clinical trials for Refractory B-Lineage Lymphoma

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Start date: December 21, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but with a higher number of doses and a two-stage phase II extension component to confirm safety and make a preliminary determination of the activity level by disease using the dose identified in phase I.